Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Haozhe ZhangYi ZhouYating FengWenli HouYafei ChenZengzhen XingYifan ZhangQiang WeiYu YinJu GuoHailiang HuPublished in: Clinical and translational medicine (2024)
CDK12 deficiency promotes castration-resistant prostate cancer (CRPC) progression by reprogramming cellular metabolism. CDK12 deficiency in CRPC leads to a more active mitochondrial electron transport chain (ETC), ensuring efficient cell energy supply. CDK12 phosphorylates RNA Pol II to ensure the transcription of ACSL4 to regulate ferroptosis. Mitochondrial ETC inhibitors exhibit better selectivity for CDK12-deficient CRPC cells, offering a promising new therapeutic approach for this subtype of CRPC patients.
Keyphrases
- cell cycle
- cell death
- cell cycle arrest
- oxidative stress
- end stage renal disease
- cell proliferation
- induced apoptosis
- ejection fraction
- newly diagnosed
- replacement therapy
- prognostic factors
- single cell
- transcription factor
- cell therapy
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- signaling pathway
- endoplasmic reticulum stress
- human health